

JUN 17 2004

PTO/SB/08a (05-01)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

Complete if Known

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	1	of	3	Attorney Docket Number	CELL-023
-------	---	----	---	------------------------	----------

U.S. PATENT DOCUMENTS

Examiner Initials ¹	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ³ (if known)			
DG	20010006633		July 5, 2001	KIRN	
DG	20010053768		December 20, 2001	GREGORY et al.	
DG	20030026789		February 6, 2003	GREGORY et al.	
DG	20030068307		April 10, 2003	YU et al.	
DG	20030104625		June 5, 2003	CHENG et al.	
DG	20040009588		January 15, 2004	CHANG et al.	
DG	5,998,205		December 7, 1999	HALLENBECK et	
DG	6,432,700		August 13, 2002	HENDERSON et	
DG	6,551,587		April 22, 2003	HALLENBECK et	
DG	6,638,762		October 28, 2003	CHANG et al.	
DG	6,692,736		February 17, 2004	YU et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials ¹	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
DG	WO 01/36650		25 May 2001	ONYX		
DG	WO 01/72341		4 Oct. 2001	CALYDON		
DG	WO 01/73093		4 Oct. 2001	CALYDON		
DG	WO 02/067861		6 Sept. 2002	NOVARTIS		
DG	WO 92/03563		5 Mar. 1992	CENTRAAL		
DG	WO 96/17053		6 June 1996	GENETIC		
DG	WO 96/34969		7 Nov. 1996	CANJI		
DG	WO 98/29555		9 July 1998	ONYX		
DG	WO 98/39464		11 Sept. 1998	CALYDON		
DG	WO 99/25860		27 May 1999	NOVARITIS		
DG	WO 99/59604		25 Nov. 1999	ONYX		
DG	WO 99/28469		10 June 1999	GENZYME		

Examiner Signature	/David Guzo/	Date Considered	06/18/2006

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 If possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

JUN 17 2004

PTO/SB/08a (05-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	2	of	3	Attorney Docket Number	CELL-023
-------	---	----	---	------------------------	----------

Complete if Known

Application Number	10/698,160
Filing Date	October 30, 2003
First Named Inventor	YU, DE-CHAO
Art Unit	1636
Examiner Name	GUZO

OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher city and/or country where published	T ²
DG		CHEN et al., LINKAGE BETWEEN STAT REGULATION AND EPSTEIN-BARR VIRUS GENE EXPRESSION IN TUMORS, J. Virol., 2001, 75(6): 2929-2937	
DG		CHIA et al., A NOVEL CONDITIONALLY ONCOLYTIC ADENOVIRUS FOR THE TREATMENT OF NASOPHARYNGEAL CARCINOMA (NPC), Proc. Amer. Ass. For Cancer Res., 2002, 43: 1098-1099	
DG		CHIOCCA et al., ONCOLYTIC VIRUSES, Nature Publishing Group, 2002, 2: 938-951	
DG		FENG et al., USE OF ADENOVIRUS VECTORS EXPRESSING EPSTEIN-BARR VIRUS (EBV) IMMEDIATE-EARLY PROTEIN BZLF1 OR BRLF1 TO TREAT EBV-POSITIVE TUMORS, J Virol., 2002, 76(21):10951-10959	
DG		GRINSTEIN et al., DEMONSTRATION OF EPSTEIN-BARR VIRUS IN CARCINOMAS OF VARIOUS SITES, Cancer Res., 2002, 1:62(17):4876-4878	
DG		LI et al., TUMOR-TARGETED GENE THERAPY FOR NASOPHARYNGEAL CARCINOMA, Cancer Res., 2002, 62: 171-178	
DG		REISMAN et al., TRANS ACTIVATION OF AN EPSTEIN-BARR VIRAL TRANSCRIPTIONAL ENHANCER BY THE EPSTEIN-BARR VIRAL NUCLEAR ANTIGEN 1, Molecular and Cell. Biol., 1986, 6(11): 3838-3846	
DG		SADLER et al., THE EPSTEIN-BARR VIRUS 3.5-KILOBASE LATENT MEMBRANE PROTEIN 1 mRNA INITIATES FROM A TATA-LESS PROMOTER WITHIN THE FIRST TERMINAL REPEAT, J. of Virol., 1995, 69(7): 4577-4581	
DG		SJÖBLOM et al., AN ATF/CRE ELEMENT MEDIATES BOTH EBNA2-DEPENDENT AND EBNA2-INDEPENDENT ACTIVATION OF THE EPSTEIN-BARR VIRUS LMP1 GENE PROMOTER, J. of Virol., 1998, 72(2): 1365-1376	

Examiner Signature	/David Guzo/	Date Considered	06/18/2006
--------------------	--------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

JUN 17 2004

PTO/SB/08a (05-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	3	of	3	Attorney Docket Number	CELL-023
-------	---	----	---	------------------------	----------

Complete if Known

Application Number	10/698,160
Filing Date	October 30, 2003
First Named Inventor	YU, DE-CHAO
Art Unit	1645 1636
Examiner Name	GUZO

OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), and other information where applicable	T ²
DG		TSAI et al., ADDITIVE EFFECT OF SP1 AND SP3 IN REGULATION OF THE ED-L1E PROMOTER OF THE EBV LMP 1 GENE IN HUMAN EPITHELIAL CELLS, Virology, 1999, 261: 288-294	
DG		YU et al., SELECTIVELY REPLICATING ONCOLYTIC ADENOVIRUSES AS CANCER THERAPEUTICS, Curr. Opinion in Mol. Ther., 2002, 4(5): 435-443	
DG		WAehler et al., EXPERIMENTAL GENE THERAPY OF HEPATOCELLULAR CARCINOMA: EXPRESSION OF IL-12, 4-1BBL AND IL-2 FROM A SINGLE ADENOVIRAL VECTOR, 10 th Annual ESGT meeting, Oct. 13-16, 2002	

Examiner Signature	/David Guzo/	Date Considered	06/18/2006
--------------------	--------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.